Anzeige
Mehr »
Login
Freitag, 07.05.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Relay Medical: 60-fache Geschwindigkeit erledigt eine unlösbare Aufgabe mit links!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JP36 ISIN: SE0010441584 Ticker-Symbol: LC8 
München
07.05.21
08:08 Uhr
11,860 Euro
-0,320
-2,63 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CALLIDITAS THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
CALLIDITAS THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur CALLIDITAS THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCalliditas promotes Andrew Udell to President, North America129STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commercial, Andrew...
► Artikel lesen
CALLIDITAS THERAPEUTICS Aktie jetzt für 0€ handeln
MoCALLIDITAS THERAPEUTICS: Calliditas promotes Andrew Udell to President, North America3
28.04.Calliditas shares rise 10% as FDA grants priority review for Nefecon1
27.04.Calliditas Therapeutics' 2020 Annual Report Published145STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...
► Artikel lesen
27.04.CALLIDITAS THERAPEUTICS: Change in financial calendar 1
26.04.Notice of annual general meeting of Calliditas Therapeutics AB (publ)143STOCKHOLM, April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general...
► Artikel lesen
23.04.Calliditas Therapeutics AB - 6-K, Report of foreign issuer1
23.04.CALLIDITAS THERAPEUTICS: EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy1
15.03.Calliditas Therapeutics AB - 6-K, Report of foreign issuer2
15.03.Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease2
15.03.Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy243STOCKHOLM, March 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA)...
► Artikel lesen
15.03.CALLIDITAS THERAPEUTICS: Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy-
08.03.Calliditas strengthens its US Commercial and Medical Affairs Organization309STOCKHOLM, March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks, PhD, as Vice President...
► Artikel lesen
08.03.CALLIDITAS THERAPEUTICS: Calliditas strengthens its US Commercial and Medical Affairs Organization3
04.03.Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice195STOCKHOLM, March 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Perspectives webinar on the Pathophysiology...
► Artikel lesen
18.02.Calliditas Therapeutics AB - 6-K, Report of foreign issuer-
18.02.Calliditas Therapeutics: Year-End Report, 2020434STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant...
► Artikel lesen
04.02.Calliditas Starts Dosing In Nefecon Open Label Extension Study In Kidney Disease2
04.02.CALLIDITAS THERAPEUTICS: First Patient Dosed in NefIgArd Open Label Extension Study-
28.01.Calliditas halts proposed global offering1
Seite:  Weiter >>
80 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1